Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs

Table 1

Patient baseline characteristics.

Characteristics	Whole group ()
Age (years)
Sex (M/F)	21/15
Diabetes duration (years)
Insulin dose (IU/d)
BMI (kg/m^2)
Body weight (kg)
Waist-to-hip radio
SBP (mmHg)
DBP (mmHg)
FBG (mmol/L)
HbA1c (%)
ALT (U/L)
eGFR (mL/min/1.73 m^2)
TC (mmol/L)
HOMA-beta
HOMA-CR
Oral hypoglycemic drugs (%)
Secretagogues	50.0
Metformin	77.8
Thiazolidine	8.3
α-Glucosidase inhibitor	52.8
DPP4 inhibitor	5.6

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; HbA1c: glycosylated hemoglobin; ALT: alanine aminotransferase; eGFR: estimated glomerular filtration rate; TC: total cholesterol; HOMA-beta: homeostasis model assessment for pancreatic beta-cell function; HOMA-CR: homeostasis model assessment of C-peptide secretion; DPP4: dipeptidase-4 inhibitor.